SOURCE: Biostem U.S., Corporation

Biostem U.S., Corporation

May 29, 2012 08:10 ET

Biostem U.S., Corporation Appoints Philip A. Lowry, MD as Chairman of Its Scientific and Medical Board of Advisors

Highly Recognized Bone Marrow Stem Cell Transplant Specialist Added to Existing Member Expertise in Maternal Fetal Medicine, Cardiology, and Pathology

CLEARWATER, FL--(Marketwire - May 29, 2012) - Biostem U.S., Corporation, (OTCQB: HAIR) (PINKSHEETS: HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, today announced that Philip A. Lowry, MD, has been appointed as the Chairman of its Scientific and Medical Board of Advisors (SAMBA).

According to Biostem CEO, Dwight Brunoehler, "As Chairman, Dr. Lowry will work with a team drawn from a cross-section of medical specialties. His combination of research, academic and community practice experience make him the perfect individual to coordinate and lead the outstanding group of physicians that makes up our SAMBA. As a group, The SAMBA will guide the company to maintain the highest ethical standards in every effort, while seeking and developing new cutting edge technology based on stem cell use. I am privileged to work with Dr. Lowry, once again."

Dr. Lowry stated, "Dwight is an innovative businessman with an eye on cutting-edge stem cell technology. His history in the industry speaks for itself. I like the plan at Biostem and look forward to working with everyone involved."

Dr. Philip A. Lowry received his undergraduate degree from Harvard College before going on to the Yale University School of Medicine. His completed his internal medicine residency at the University of Virginia then pursued fellowship training in hematology and oncology there as well. During fellowship training and subsequently at the University of Massachusetts, he worked in the laboratory of Dr. Peter Quesenberry working on in vitro and in vivo studies of mouse and human stem cell biology.

Dr. Lowry twice served on the faculty at the University of Massachusetts Medical Center from 1992-1996 and from 2004-2009 as an assistant and then associate clinical professor of medicine establishing the bone marrow/stem cell transplantation program there, serving as medical director of the Cryopreservation Lab supporting the transplant program, helping to develop a cord blood banking program, and teaching and coordinating the second year medical school course in hematology and oncology. Dr. Lowry additionally has ten years experience in the community practice of hematology and oncology. In 2010, Dr. Lowry became chief of hematology/oncology for the Guthrie Health System, a three-hospital tertiary care system serving northern Pennsylvania and southern New York State. He is charged with developing a cutting-edge cancer program that can project into a traditionally rural health care delivery system.

Dr. Lowry has also maintained a career-long interest in regenerative medicine springing from his research and practice experience in stem cell biology. His new role positions him to foster further development of that field. As part of a horizontally and vertically integrated multi-specialty team, he is closely allied with colleagues in cardiology, neurology/neurosurgery, and orthopedics among others with whom he hopes to stimulate the expansion of regenerative techniques.

About Biostem U.S., Corporation

Biostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell-related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through, or by calling Fox Communications Group 310-974-6821.

Contact Information

  • Contact:
    Fox Communications Group